Publications
Filters: First Letter Of Title is P [Clear All Filters]
“Plasmodium-infected erythrocytes induce secretion of IGFBP7 to form type II rosettes and escape phagocytosis”, eLife, vol. 9, p. e51546, 2020.
, “Pregnancy outcomes and risk of placental malaria after artemisinin-based and quinine-based treatment for uncomplicated falciparum malaria in pregnancy: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis”, BMC Medicine, vol. 18, no. 1, p. 138, 2020.
, “Prevalence and determinants of perinatal depression among labour migrant and refugee women on the Thai-Myanmar border: a cohort study”, BMC Psychiatry, vol. 20, no. 1, p. 168, 2020.
, “Prevention of mother-to-child transmission of hepatitis B virus: protocol for a one-arm, open-label intervention study to estimate the optimal timing of tenofovir in pregnancy”, BMJ Open, vol. 10, no. 9, p. e038123, 2020.
, “Pairwise growth competitions identify relative fitness relationships among artemisinin resistant Plasmodium falciparum field isolates”, Malar J, vol. 18, no. 1, p. 295, 2019.
, “Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis”, PLoS Med, vol. 16, no. 12, p. e1002992, 2019.
, “Pharmacokinetics of oral tenofovir disoproxil fumarate in pregnancy and lactation: a systematic review”, Antivir Ther, 2019.
, “Plasmodium vivax Relapse Rates Following Plasmodium falciparum Malaria Reflect Previous Transmission Intensity”, J Infect Dis, vol. 220, no. 1, pp. 100-104, 2019.
, “Polymorphisms in Pvkelch12 and gene amplification of Pvplasmepsin4 in Plasmodium vivax from Thailand, Lao PDR and Cambodia”, Malar J, vol. 18, no. 1, p. 114, 2019.
, “Potential herd protection against Plasmodium falciparum infections conferred by mass antimalarial drug administrations”, Elife, vol. 8, 2019.
, “The probability of a sequential Plasmodium vivax infection following asymptomatic Plasmodium falciparum and P. vivax infections in Myanmar, Vietnam, Cambodia, and Laos”, Malar J, vol. 18, no. 1, p. 449, 2019.
, “A prospective cohort for the investigation of alteration in temporal transcriptional and microbiome trajectories preceding preterm birth: a study protocol”, BMJ Open, vol. 9, no. 1, p. e023417, 2019.
, “Plasmodium vivax Merozoite Surface Protein 1 Paralog as a Mediator of Parasite Adherence to Reticulocytes”, Infect Immun, vol. 86, no. 9, 2018.
, “Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening”, International Journal of Neonatal Screening, vol. 4, p. 34, 2018.
, “Poor response to artesunate treatment in two patients with severe malaria on the Thai-Myanmar border”, Malar J, vol. 17, no. 1, p. 30, 2018.
, “Population pharmacokinetics of the antimalarial amodiaquine: A pooled analysis to optimize dosing”, Antimicrobial agents and chemotherapy, pp. AAC. 02193-17, 2018.
, “Primaquine Pharmacokinetics in Lactating Women and Breastfed Infant Exposures”, Clin Infect Dis, 2018.
, “Primaquine-induced haemolysis in females heterozygous for G6PD deficiency”, Malar J, vol. 17, no. 1, p. 101, 2018.
, , “P. falciparum infection and maternofetal antibody transfer in malaria-endemic settings of varying transmission”, PLoS One, vol. 12, no. 10, p. e0186577, 2017.
, “Performance of a High-Sensitivity Rapid Diagnostic Test for Plasmodium falciparum Malaria in Asymptomatic Individuals from Uganda and Myanmar and Naive Human Challenge Infections”, Am J Trop Med Hyg, 2017.
, “Plasmodium falciparum Kelch 13 mutations and treatment response in patients in Hpa-Pun District, Northern Kayin State, Myanmar”, Malaria Journal, vol. 16, no. 1, p. 480, 2017.
, “Plasmodium P36 determines host cell receptor usage during sporozoite invasion”, Elife, vol. 6, 2017.
, “The Plasmodium PI(4)K inhibitor KDU691 selectively inhibits dihydroartemisinin-pretreated Plasmodium falciparum ring-stage parasites”, Sci Rep, vol. 7, no. 1, p. 2325, 2017.
, “Plasmodium vivax genetic diversity and heterozygosity in blood samples and resulting oocysts at the Thai-Myanmar border”, Malar J, vol. 16, no. 1, p. 355, 2017.
, “Plasmodium vivax rhomboid-like protease 1 gene diversity in Thailand”, Exp Parasitol, vol. 181, pp. 1-6, 2017.
, “Population Parameters Underlying an Ongoing Soft Sweep in Southeast Asian Malaria Parasites”, Mol Biol Evol, vol. 34, no. 1, pp. 131-144, 2017.
, “Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia”, AAPS J, 2017.
, “Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine”, Antimicrob Agents Chemother, 2017.
, , “Paired suicide in a young refugee couple on the Thai-Myanmar border”, BMJ Case Rep, vol. 2016, 2016.
, “Population Structure Shapes Copy Number Variation in Malaria Parasites”, Molecular Biology and Evolution, vol. 33, no. 3, pp. 603-20, 2016.
, , “Perceived Benefits, Harms, and Views About How to Share Data Responsibly: A Qualitative Study of Experiences With and Attitudes Toward Data Sharing Among Research Staff and Community Representatives in Thailand”, J Empir Res Hum Res Ethics, vol. 10, no. 3, pp. 278-89, 2015.
, “Performance of BinaxNOW G6PD deficiency point-of-care diagnostic in P. vivax-infected subjects”, Am J Trop Med Hyg, vol. 92, no. 1, pp. 22-7, 2015.
, “Performance of C-reactive protein and procalcitonin to distinguish viral from bacterial and malarial causes of fever in Southeast Asia”, BMC Infect Dis, vol. 15, no. 1, p. 511, 2015.
, “Pharmacokinetic interactions between primaquine and pyronaridine-artesunate in healthy adult Thai subjects”, Antimicrob Agents Chemother, vol. 59, no. 1, pp. 505-13, 2015.
, “Plasmodium falciparum genetic crosses in a humanized mouse model”, Nat Methods, vol. 12, no. 7, pp. 631-3, 2015.
, “Plasmodium vivax malaria: challenges in diagnosis, treatment and elimination”, Pediatr Infect Dis J, vol. 34, no. 5, pp. 529-31, 2015.
, “Pooled sequencing and rare variant association tests for identifying the determinants of emerging drug resistance in malaria parasites”, Mol Biol Evol, vol. 32, no. 4, pp. 1080-90, 2015.
, “Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria”, Clin Pharmacol Ther, vol. 98, no. 1, pp. 87-95, 2015.
, “Preclinical assessment of viral vectored and protein vaccines targeting the Duffy-binding protein region II of Plasmodium vivax”, Frontiers in Immunology, vol. 6, 2015.
, “Pregnant migrant and refugee women's perceptions of mental illness on the Thai-Myanmar border: a qualitative study”, BMC Pregnancy Childbirth, vol. 15, p. 93, 2015.
, “Plasmodium vivax: restricted tropism and rapid remodelling of CD71 positive reticulocytes”, Blood, 2014.
, “PlasmoView: a web-based resource to visualise global Plasmodium falciparum genomic variation”, J Infect Dis, vol. 209, no. 11, pp. 1808-15, 2014.
, “Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine”, Am J Trop Med Hyg, vol. 91, no. 4, pp. 833-43, 2014.
, “Population pharmacokinetic assessment of the effect of food on piperaquine bioavailability in patients with uncomplicated malaria”, Antimicrob Agents Chemother, vol. 58, no. 4, pp. 2052-2058, 2014.
, “Population Pharmacokinetics and Antimalarial Pharmacodynamics of Piperaquine in Patients With Plasmodium vivax Malaria in Thailand”, CPT: pharmacomet. syst. pharmacol., vol. 3, p. e132, 2014.
, “Population pharmacokinetics of quinine in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda”, J Antimicrob Chemother, vol. 69, no. 11, pp. 3033-40, 2014.
, “Pregnancy outcome in relation to treatment of murine typhus and scrub typhus infection: a Fever cohort and a case series analysis”, PLoS Negl Trop Dis, vol. 8, no. 11, p. e3327, 2014.
, “Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infants”, J Infect Dis, vol. 207, no. 11, pp. 1646-54, 2013.
, “Pharmacokinetic Properties of Artemether, Dihydroartemisinin, Lumefantrine, and Quinine in Pregnant Women with Uncomplicated Plasmodium falciparum Malaria in Uganda”, Antimicrob Agents Chemother, vol. 57, no. 10, pp. 5096-103, 2013.
, “Population genetic correlates of declining transmission in a human pathogen”, Mol Ecol, vol. 22, no. 2, pp. 273-85, 2013.
, “Population Pharmacokinetics of Lumefantrine in Pregnant and Nonpregnant Women With Uncomplicated Plasmodium falciparum Malaria in Uganda”, CPT Pharmacometrics Syst Pharmacol, vol. 2, p. e83, 2013.
, “The practicality and sustainability of a community advisory board at a large medical research unit on the Thai-Myanmar border”, Health, vol. 05, no. 02, pp. 229-236, 2013.
, , “pfmdr1 amplification is related to increased Plasmodium falciparum in vitro sensitivity to the bisquinoline piperaquine”, Antimicrob Agents Chemother, vol. 56, no. 7, pp. 3615-9, 2012.
, “Pharmacokinetics of Piperaquine in Pregnant Women in Sudan with Uncomplicated Plasmodium falciparum Malaria”, Am J Trop Med Hyg, vol. 87, no. 1, pp. 35-40, 2012.
, “Population Pharmacokinetic and Pharmacodynamic Modeling of Amodiaquine and Desethylamodiaquine in Women with Plasmodium vivax Malaria during and after Pregnancy”, Antimicrob Agents Chemother, vol. 56, no. 11, pp. 5764-5773, 2012.
, “A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan”, Malar J, vol. 11, no. 1, p. 398, 2012.
, “Population Pharmacokinetics and Pharmacodynamics of Piperaquine in Children With Uncomplicated Falciparum Malaria”, CLIN PHARMACOL THER, vol. 91, no. 3, pp. 497-505, 2012.
, “Population pharmacokinetics of Artemether and dihydroartemisinin in pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda”, Malar J, vol. 11, no. 1, p. 293, 2012.
, “Population pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated malaria”, Antimicrob Agents Chemother, vol. 56, no. 4, pp. 1997-2007, 2012.
, “Population pharmacokinetics of halofantrine in healthy volunteers and patients with symptomatic falciparum malaria”, Journal of Pharmacy and Pharmacology, vol. 64, no. 11, pp. 1603-1613, 2012.
, “Primaquine radical cure of Plasmodium vivax: a critical review of the literature”, Malar J, vol. 11, no. 1, p. 280, 2012.
, “Proxies and prevention of malaria in pregnancy”, Lancet Infect Dis, 2012.
, “Pyronaridine-artesunate versus mefloquine plus artesunate for malaria”, N Engl J Med, vol. 366, no. 14, pp. 1298-309, 2012.
, “Pharmacokinetics of amodiaquine and desethylamodiaquine in pregnant and postpartum women with Plasmodium vivax malaria”, Antimicrob Agents Chemother, vol. 55, no. 9, pp. 4338-42, 2011.
, “Pharmacokinetics of dihydroartemisinin and piperaquine in pregnant and nonpregnant women with uncomplicated falciparum malaria”, Antimicrob Agents Chemother, vol. 55, no. 12, pp. 5500-6, 2011.
, “Plasmodium vivax lineages: geographical distribution, tandem repeat polymorphism, and phylogenetic relationship”, Malar J, vol. 10, no. 1, p. 374, 2011.
, “Plasmodium vivax recurrence following falciparum and mixed species malaria: risk factors and effect of antimalarial kinetics”, Clin Infect Dis, vol. 52, no. 5, pp. 612-20, 2011.
, “Population genetic analysis of Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assay”, PLoS ONE, vol. 6, no. 6, p. e20251, 2011.
, “The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum”, Antimicrob Agents Chemother, vol. 55, no. 3, pp. 1300-4, 2011.
, “A prospective evaluation of diagnostic methodologies for the acute diagnosis of dengue virus infection on the Thailand-Myanmar border”, Trans R Soc Trop Med Hyg, vol. 105, no. 1, pp. 32-7, 2011.
, “A prospective study of urinary pneumococcal antigen detection in healthy Karen mothers with high rates of pneumococcal nasopharyngeal carriage”, BMC Infect Dis, vol. 11, p. 108, 2011.
, “Plasmodium vivax susceptibility to ferroquine”, Antimicrob Agents Chemother, vol. 54, no. 5, pp. 2228-30, 2010.
, “Population pharmacokinetics of antimalarial drugs in the treatment of pregnant women with uncomplicated malaria”, in 59th Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, USA, 2010, vol. 83, p. 2.
, “Pyronaridine-artesunate for uncomplicated falciparum malaria”, Lancet, vol. 375, no. 9724, pp. 1413-4, 2010.
, “Placental malaria in areas of different endemicity: a modified pathological grading scheme”, in 58th Meeting of the American Society of Tropical Medicine and Hygiene, Washington DC, USA, 2009, vol. 81, p. 39.
, “Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria”, Antimicrob Agents Chemother, vol. 53, no. 9, pp. 3837-46, 2009.
, “Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity”, Malar J, vol. 7, no. 1, p. 249, 2008.
, “Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar”, Trop Med Int Health, vol. 13, no. 1, pp. 91-8, 2008.
, “Plasmodium vivax trophozoites insensitive to chloroquine”, Malar J, vol. 7, no. 1, p. 94, 2008.
, “Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand”, Antimicrob Agents Chemother, vol. 52, no. 3, pp. 1052-61, 2008.
, “Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria”, Trop Med Int Health, vol. 12, no. 2, pp. 201-8, 2007.
, “Population pharmacokinetics of piperaquine after two different treatment regimens of dihydroartemisinin-piperaquine in patients with acute uncomplicated falciparum malaria in Thailand”, in 5th European Congress on Tropical Medicine and International Health, Amsterdam, the Netherlands, 2007, vol. 12, p. 222.
, “The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria”, Eur J Clin Pharmacol, vol. 62, no. 12, pp. 1021-31, 2006.
, “Pharmacokinetics of dihydroartemisinin following oral artesunate treatment of pregnant women with acute uncomplicated falciparum malaria”, Eur J Clin Pharmacol, vol. 62, no. 5, pp. 367-71, 2006.
, “Plasmodium vivax: isotopic, PicoGreen, and microscopic assays for measuring chloroquine sensitivity in fresh and cryopreserved isolates”, Exp Parasitol, vol. 114, no. 1, pp. 34-9, 2006.
, “Population pharmacokinetic assessment of a new regimen of mefloquine used in combination treatment of uncomplicated falciparum malaria”, Antimicrob Agents Chemother, vol. 50, no. 7, pp. 2281-5, 2006.
, “Population pharmacokinetics of artesunate and dihydroartemisinin following intra-rectal dosing of artesunate in malaria patients”, PLoS Med, vol. 3, no. 11, p. e444, 2006.
, “Pharmacokinetics of oral doxycycline during combination treatment of severe falciparum malaria”, Antimicrob Agents Chemother, vol. 49, no. 4, pp. 1622-5, 2005.
, “Photoallergy to quinine”, Trop Doct, vol. 35, no. 2, pp. 117-8, 2005.
, “The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria”, European Journal of Clinical Pharmacology, vol. 59, no. 7, pp. 545-552, 2003.
, “Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil”, European Journal of Clinical Pharmacology, vol. 59, no. 7, pp. 553-557, 2003.
, “Paracheck-Pf: a new, inexpensive and reliable rapid test for P. falciparum malaria”, Tropical Medicine and International Health, vol. 6, no. 2, pp. 99-101., 2001.
, “Postpartum thiamine deficiency in a Karen displaced population”, American Journal of Clinical Nutrition, vol. 74, no. 6, pp. 808-813, 2001.
, “Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria”, Antimicrob Agents Chemother, vol. 44, no. 3, pp. 697-704, 2000.
, “Plasmodium falciparum antimalarial drug susceptibility on the north- western border of Thailand during five years of extensive use of artesunate-mefloquine”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 94, no. 5, pp. 537-44., 2000.
, “Prophylactic effect of Malarone against malaria: all good news?”, Lancet, vol. 356, no. 9245, pp. 1864-5, 2000.
, “The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand”, Antimicrob Agents Chemother, vol. 43, no. 12, pp. 2943-9, 1999.
, “Pharmacokinetics of mefloquine combined with artesunate in children with acute falciparum malaria”, Antimicrob Agents Chemother, vol. 43, no. 2, pp. 341-6, 1999.
, “Population pharmacokinetics of mefloquine in patients with acute falciparum malaria”, Clinical Pharmacology and Therapeutics, vol. 66, no. 5, pp. 472-84, 1999.
, “Prolongation of the QTc interval in African children treated for falciparum malaria”, American Journal of Tropical Medicine and Hygiene, vol. 59, no. 4, p. 503, 1998.
, “Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia”, Am J Trop Med Hyg, vol. 56, no. 5, pp. 526-32, 1997.
, “Predictors of mefloquine treatment failure: a prospective study of 1590 patients with uncomplicated falciparum malaria”, Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 89, no. 6, pp. 660-4, 1995.
,